Molecular profiling of tumor-specific T_H1 cells activated in vivo

References

• Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994; 179:1215 - 24; http://dx.doi.org/10.1084/jem.179.4.1215; PMID: 7908321
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188:2357 - 68; http://dx.doi.org/10.1084/jem.188.12.2357; PMID: 9858522
   PubMed Web of Science ®Google Scholar
• Ossendorp F, Mengedé E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187:693 - 702; http://dx.doi.org/10.1084/jem.187.5.693; PMID: 9480979
   PubMed Web of Science ®Google Scholar
• Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588 - 94; http://dx.doi.org/10.1016/S0952-7915(98)80228-8; PMID: 9794842
   PubMed Web of Science ®Google Scholar
• Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, et al. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047 - 55; PMID: 11086036
   PubMed Web of Science ®Google Scholar
• Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22:371 - 83; http://dx.doi.org/10.1016/j.immuni.2005.02.003; PMID: 15780993
   PubMed Web of Science ®Google Scholar
• Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, et al. CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 2003; 63:1555 - 9; PMID: 12670904
   PubMed Web of Science ®Google Scholar
• Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006; 28:1089 - 98; PMID: 16596224
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298 - 306; http://dx.doi.org/10.1038/nrc3245; PMID: 22419253
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443 - 54; http://dx.doi.org/10.1056/NEJMoa1200690; PMID: 22658127
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455 - 65; http://dx.doi.org/10.1056/NEJMoa1200694; PMID: 22658128
   PubMed Web of Science ®Google Scholar
• Bogen B, Gleditsch L, Weiss S, Dembic Z. Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol 1992; 22:703 - 9; http://dx.doi.org/10.1002/eji.1830220313; PMID: 1547816
   PubMed Web of Science ®Google Scholar
• Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 1994; 91:5700 - 4; http://dx.doi.org/10.1073/pnas.91.12.5700; PMID: 7911244
   PubMed Web of Science ®Google Scholar
• Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, et al. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 1995; 25:3079 - 86; http://dx.doi.org/10.1002/eji.1830251114; PMID: 7489746
   PubMed Web of Science ®Google Scholar
• Lauritzsen GF, Bogen B. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 1993; 148:177 - 88; http://dx.doi.org/10.1006/cimm.1993.1100; PMID: 8098665
   PubMed Web of Science ®Google Scholar
• Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res 2009; 69:5901 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-08-4816; PMID: 19567679
   PubMed Web of Science ®Google Scholar
• Dembic Z, Schenck K, Bogen B. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A 2000; 97:2697 - 702; http://dx.doi.org/10.1073/pnas.050579897; PMID: 10706628
   PubMed Web of Science ®Google Scholar
• Lorvik KB, Bogen B, Corthay A. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood 2012; 119:2176 - 7; http://dx.doi.org/10.1182/blood-2011-10-388892; PMID: 22383793
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Lorvik KB, Hammarström C, Donaldson IM, Haraldsen G, Bogen B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun 2011; 2:240; http://dx.doi.org/10.1038/ncomms1239; PMID: 21407206
   PubMed Web of Science ®Google Scholar
• Haabeth OA, Bogen B, Corthay A. A model for cancer-suppressive inflammation. Oncoimmunology 2012; 1:1146 - 55; http://dx.doi.org/10.4161/onci.21542; PMID: 23170261
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112:1557 - 69; http://dx.doi.org/10.1182/blood-2008-05-078154; PMID: 18725574
   PubMed Web of Science ®Google Scholar
• Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296:1634 - 5; http://dx.doi.org/10.1126/science.1071924; PMID: 12040173
   PubMed Web of Science ®Google Scholar
• Li MO, Flavell RA. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 2008; 28:468 - 76; http://dx.doi.org/10.1016/j.immuni.2008.03.003; PMID: 18400189
   PubMed Web of Science ®Google Scholar
• Robb RJ, Munck A, Smith KA. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med 1981; 154:1455 - 74; http://dx.doi.org/10.1084/jem.154.5.1455; PMID: 6975347
   PubMed Web of Science ®Google Scholar
• López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, et al. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993; 178:537 - 47; http://dx.doi.org/10.1084/jem.178.2.537; PMID: 8340758
   PubMed Web of Science ®Google Scholar
• Wei G, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 2009; 30:155 - 67; http://dx.doi.org/10.1016/j.immuni.2008.12.009; PMID: 19144320
   PubMed Web of Science ®Google Scholar
• Heng TS, Painter MW, Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 2008; 9:1091 - 4; http://dx.doi.org/10.1038/ni1008-1091; PMID: 18800157
   PubMed Web of Science ®Google Scholar
• Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, et al. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 2001; 19:23 - 45; http://dx.doi.org/10.1146/annurev.immunol.19.1.23; PMID: 11244029
   PubMed Web of Science ®Google Scholar
• Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27:591 - 619; http://dx.doi.org/10.1146/annurev.immunol.021908.132706; PMID: 19132916
   PubMed Web of Science ®Google Scholar
• Nandi A, Estess P, Siegelman M. Bimolecular complex between rolling and firm adhesion receptors required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity 2004; 20:455 - 65; http://dx.doi.org/10.1016/S1074-7613(04)00077-9; PMID: 15084274
   PubMed Web of Science ®Google Scholar
• Baaten BJ, Li CR, Deiro MF, Lin MM, Linton PJ, Bradley LM. CD44 regulates survival and memory development in Th1 cells. Immunity 2010; 32:104 - 15; http://dx.doi.org/10.1016/j.immuni.2009.10.011; PMID: 20079666
   PubMed Web of Science ®Google Scholar
• Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, et al. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol 1985; 135:2331 - 6; PMID: 3928743
   PubMed Web of Science ®Google Scholar
• Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol 2010; 22:326 - 32; http://dx.doi.org/10.1016/j.coi.2010.01.001; PMID: 20116985
   PubMed Web of Science ®Google Scholar
• Bogunovic D, O’Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 2009; 106:20429 - 34; http://dx.doi.org/10.1073/pnas.0905139106; PMID: 19915147
   PubMed Web of Science ®Google Scholar
• Arens R, Tesselaar K, Baars PA, van Schijndel GM, Hendriks J, Pals ST, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001; 15:801 - 12; http://dx.doi.org/10.1016/S1074-7613(01)00236-9; PMID: 11728341
   PubMed Web of Science ®Google Scholar
• Tang C, Yamada H, Shibata K, Muta H, Wajjwalku W, Podack ER, et al. A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol 2008; 181:6316 - 27; PMID: 18941223
   PubMed Web of Science ®Google Scholar
• Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005; 23:515 - 48; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115611; PMID: 15771580
   PubMed Web of Science ®Google Scholar
• Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat Rev Immunol 2007; 7:238 - 43; http://dx.doi.org/10.1038/nri2020; PMID: 17290299
   PubMed Web of Science ®Google Scholar
• Hakamada-Taguchi R, Kato T, Ushijima H, Murakami M, Uede T, Nariuchi H. Expression and co-stimulatory function of B7-2 on murine CD4+ T cells. Eur J Immunol 1998; 28:865 - 73; http://dx.doi.org/10.1002/(SICI)1521-4141(199803)28:03<865::AID-IMMU865>3.0.CO;2-T; PMID: 9541581
   PubMed Web of Science ®Google Scholar
• Jeannin P, Herbault N, Delneste Y, Magistrelli G, Lecoanet-Henchoz S, Caron G, et al. Human effector memory T cells express CD86: a functional role in naive T cell priming. J Immunol 1999; 162:2044 - 8; PMID: 9973476
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13:114 - 9; http://dx.doi.org/10.1016/S0952-7915(00)00191-6; PMID: 11154927
   PubMed Web of Science ®Google Scholar
• Josien R, Wong BR, Li HL, Steinman RM, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162:2562 - 8; PMID: 10072496
   PubMed Web of Science ®Google Scholar
• Ma L, Mauro C, Cornish GH, Chai JG, Coe D, Fu H, et al. Ig gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and tolerance. Proc Natl Acad Sci U S A 2010; 107:19461 - 6; http://dx.doi.org/10.1073/pnas.1011748107; PMID: 20978210
   PubMed Web of Science ®Google Scholar
• Newton-Nash DK, Newman PJ. A new role for platelet-endothelial cell adhesion molecule-1 (CD31): inhibition of TCR-mediated signal transduction. J Immunol 1999; 163:682 - 8; PMID: 10395658
   PubMed Web of Science ®Google Scholar
• Suto A, Wurster AL, Reiner SL, Grusby MJ. IL-21 inhibits IFN-gamma production in developing Th1 cells through the repression of Eomesodermin expression. J Immunol 2006; 177:3721 - 7; PMID: 16951332
   PubMed Web of Science ®Google Scholar
• Yang Y, Xu J, Niu Y, Bromberg JS, Ding Y. T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol 2008; 181:8700 - 10; PMID: 19050290
   PubMed Web of Science ®Google Scholar
• Brunner C, Sindrilaru A, Girkontaite I, Fischer KD, Sunderkötter C, Wirth T. BOB.1/OBF.1 controls the balance of TH1 and TH2 immune responses. EMBO J 2007; 26:3191 - 202; http://dx.doi.org/10.1038/sj.emboj.7601742; PMID: 17568779
   PubMed Web of Science ®Google Scholar
• Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005; 310:1159 - 63; http://dx.doi.org/10.1126/science.1117893; PMID: 16293754
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011; 23:598 - 604; http://dx.doi.org/10.1016/j.coi.2011.08.003; PMID: 21889323
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708 - 12; http://dx.doi.org/10.1038/44385; PMID: 10537110
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405 - 13; http://dx.doi.org/10.1016/1074-7613(94)90071-X; PMID: 7882171
   PubMed Web of Science ®Google Scholar
• Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol 2008; 66:52 - 64; http://dx.doi.org/10.1016/j.critrevonc.2008.01.002; PMID: 18289867
   PubMed Web of Science ®Google Scholar
• Minas K, Liversidge J. Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?. Crit Rev Immunol 2006; 26:213 - 30; http://dx.doi.org/10.1615/CritRevImmunol.v26.i3.20; PMID: 16928187
   PubMed Web of Science ®Google Scholar
• Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007; 19:309 - 14; http://dx.doi.org/10.1016/j.coi.2007.04.012; PMID: 17433872
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027 - 34; http://dx.doi.org/10.1084/jem.192.7.1027; PMID: 11015443
   PubMed Web of Science ®Google Scholar
• James JR, Vale RD. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 2012; 487:64 - 9; PMID: 22763440
   PubMed Web of Science ®Google Scholar
• Birkeland ML, Kraus T, Tardelli L, Puré E. Progressive changes in CD45RB phenotype and lymphokine production by murine CD4+ T cells after alloantigen exposure. Immunology 1992; 75:632 - 8; PMID: 1350569
   PubMed Web of Science ®Google Scholar
• Wolenski M, Cramer SO, Ehrlich S, Steeg C, Fleischer B, von Bonin A. Enhanced activation of CD83-positive T cells. Scand J Immunol 2003; 58:306 - 11; http://dx.doi.org/10.1046/j.1365-3083.2003.01303.x; PMID: 12950676
   PubMed Web of Science ®Google Scholar
• Haeryfar SM, Hoskin DW. Thy-1: more than a mouse pan-T cell marker. J Immunol 2004; 173:3581 - 8; PMID: 15356100
   PubMed Web of Science ®Google Scholar
• Bowen MA, Bajorath J, D’Egidio M, Whitney GS, Palmer D, Kobarg J, et al. Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol 1997; 27:1469 - 78; http://dx.doi.org/10.1002/eji.1830270625; PMID: 9209500
   PubMed Web of Science ®Google Scholar
• Caruso A, Licenziati S, Corulli M, Canaris AD, De Francesco MA, Fiorentini S, et al. Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation. Cytometry 1997; 27:71 - 6; http://dx.doi.org/10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO;2-O; PMID: 9000587
   PubMedGoogle Scholar
• Corthay A. How do regulatory T cells work?. Scand J Immunol 2009; 70:326 - 36; http://dx.doi.org/10.1111/j.1365-3083.2009.02308.x; PMID: 19751267
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128 - 38; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606; PMID: 23135914
   PubMed Web of Science ®Google Scholar
• Eisen HN, Simms ES, Potter M. Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315. Biochemistry 1968; 7:4126 - 34; http://dx.doi.org/10.1021/bi00851a048; PMID: 4177521
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:e3; http://dx.doi.org/10.2202/1544-6115.1027; PMID: 16646809
   PubMedGoogle Scholar
• Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44 - 57; http://dx.doi.org/10.1038/nprot.2008.211; PMID: 19131956
   PubMed Web of Science ®Google Scholar
• Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37:1 - 13; http://dx.doi.org/10.1093/nar/gkn923; PMID: 19033363
   PubMed Web of Science ®Google Scholar